Jointown announced that its controlled subsidiary has added two products to the National Essential Medicines List, 2026 Edition, which will take effect on September 1, 2026. The new additions will help expand the coverage of the related products in medical institutions at all levels, positively impacting the company's product market expansion. In the first quarter of 2026, Jointown achieved revenue of 44.783 billion yuan and net profit attributable to the parent company of 733 million yuan.
Jointown Pharmaceutical Group Co LtdTwo products added to National Essential Medicines List, expanding hospital coverage and boosting product market expansion.